Next Article in Journal
Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
Next Article in Special Issue
Mucosal Vaccination via the Respiratory Tract
Previous Article in Journal
Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled In Silico-Experimental Studies. Part I: Covalent siRNA Nanocarriers
Previous Article in Special Issue
Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary Phospholipidosis
Open AccessReview

Inhaled Antibiotics for Mycobacterial Lung Disease

Department of Research and Development, Qrumpharma Inc., Doylestown, PA 18901, USA
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(7), 352; https://doi.org/10.3390/pharmaceutics11070352
Received: 27 May 2019 / Revised: 9 July 2019 / Accepted: 15 July 2019 / Published: 19 July 2019
(This article belongs to the Special Issue Advances in Pulmonary Drug Delivery)
Mycobacterial lung diseases are an increasing global health concern. Tuberculosis and nontuberculous mycobacteria differ in disease severity, epidemiology, and treatment strategies, but there are also a number of similarities. Pathophysiology and disease progression appear to be relatively similar between these two clinical diagnoses, and as a result these difficult to treat pulmonary infections often require similarly extensive treatment durations of multiple systemic drugs. In an effort to improve treatment outcomes for all mycobacterial lung diseases, a significant body of research has investigated the use of inhaled antibiotics. This review discusses previous research into inhaled development programs, as well as ongoing research of inhaled therapies for both nontuberculous mycobacterial lung disease, and tuberculosis. Due to the similarities between the causative agents, this review will also discuss the potential cross-fertilization of development programs between these similar-yet-different diseases. Finally, we will discuss some of the perceived difficulties in developing a clinically utilized inhaled antibiotic for mycobacterial diseases, and potential arguments in favor of the approach. View Full-Text
Keywords: inhalation; antimicrobials; tuberculosis; nontuberculous mycobacteria inhalation; antimicrobials; tuberculosis; nontuberculous mycobacteria
Show Figures

Graphical abstract

MDPI and ACS Style

Banaschewski, B.; Hofmann, T. Inhaled Antibiotics for Mycobacterial Lung Disease. Pharmaceutics 2019, 11, 352.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop